Effect of Mocozift on Tuberculosis

The efficacy of Mocozift syrup on the clinical symptoms of pulmonary tuberculosis patients : A pilot randomized double-blind placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250907067164N1

Enrollment

Registered

2025-11-26

Start date

2025-11-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis. Respiratory tuberculosis

Interventions

Intervention 1: Intervention group: Patients receiving standard anti-tuberculosis treatment (according to the national DOTs program) plus Mocosift oral syrup (Behdaneh Baran Co., 10 mL, three times da

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: pulmonary tuberculosis diagnosis Willingness to participate in the study (informed consent). No history of HIV infection. Not pregnant or breastfeeding.

Exclusion criteria

Exclusion criteria: Patients with any underlying disease. Patients with inadequate verbal communication. Patients unable to tolerate oral intake.

Design outcomes

Primary

Measure	Time frame
Cough Number. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Cough Severity Visual Analog Scale Assessment.;Appetite Score. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: The Simplified Nutritional Appetite Questionnaire (SNAQ).;Fatigue Severity. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Fatigue Severity Scale (FSS).;Complication rate. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Clinical Assessment.	—

Measure

Time frame

Cough Number. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Cough Severity Visual Analog Scale Assessment.;Appetite Score. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: The Simplified Nutritional Appetite Questionnaire (SNAQ).;Fatigue Severity. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Fatigue Severity Scale (FSS).;Complication rate. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Clinical Assessment.

—

Secondary

Measure	Time frame
Aspartate Aminotransferase Serum Level. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Colorimetric Enzymatic Assay Method.;Alanine Aminotransferase Serum Level. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Colorimetric Enzymatic Assay Method.;Alkaline Phosphatase Serum Level. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Colorimetric Enzymatic Assay Method.	—

Measure

Time frame

Aspartate Aminotransferase Serum Level. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Colorimetric Enzymatic Assay Method.;Alanine Aminotransferase Serum Level. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Colorimetric Enzymatic Assay Method.;Alkaline Phosphatase Serum Level. Timepoint: At the beginning of the study (before the intervention) and at 14 and 28 days after the treatment period. Method of measurement: Colorimetric Enzymatic Assay Method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojgan Khadem Sadarkhani

Yazd University of Medical Sciences

mojgansafdarkhani@gmail.comCentral Administration, Bahonar Sq.

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026